Search

Your search keyword '"Foeldvari, I."' showing total 827 results

Search Constraints

Start Over You searched for: Author "Foeldvari, I." Remove constraint Author: "Foeldvari, I."
827 results on '"Foeldvari, I."'

Search Results

1. AB1701 IS THERE A DIFFERENCE IN THE NUMBER OF INVOLVED ORGAN SYSTEMS BETWEEN JUVENILE DIFFUSE AND LIMITED SUBTYPE SYSTEMIC SCLEROSIS PATIENTS?

2. AB1717 GUIDANCE FOR STEM CELL THERAPY FOR JUVENILE SYSTEMIC SCLEROSIS PATIENTS

3. LBA0009 EFFICACY AND SAFETY OF IXEKIZUMAB IN CHILDREN WITH ACTIVE JUVENILE PSORIATIC ARTHRITIS AND ENTHESITIS RELATED ARTHRITIS (COSPIRIT-JIA): 16-WEEK RESULTS OF A MULTICENTRE, RANDOMISED, OPEN-LABEL STUDY

5. POS0758 PRESENCE OF NAILFOLD CAPILLARY CHANGES CORRELATES WITH MORE SEVERE ORGAN INVOLVEMENT IN JUVENILE SYSTEMIC SCLERODERMA. RESULTS OF THE JUVENILE SCLERODERMA INCEPTION COHORT.

6. OP0087 PHYSICAL ACTIVITY, SCREEN TIME AND HEALTH RELATED QUALITY OF LIFE AMONG ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS

7. POS0770 DIFFERENCES IN CLINICAL PRESENTATION BETWEEN JUVENILE SYSTEMIC SCLEROSIS PATIENTS WITH DIFFUSE AND LIMITED SUBTYPE. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT.

8. OP0211 TREAT-TO-TARGET IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS - A PROTOCOLS IN PAEDIATRIC RHEUMATOLOGY (PROKIND) STUDY

9. Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

11. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis

12. POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL

15. OP0161 24 MONTH RESULTS ON EFFECTIVENESS AND SAFETY OF A COMPARATIVE STUDY OF TOCILIZUMAB VERSUS TUMOUR NECROSIS FACTOR INHIBITION IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

16. POS0139 DIFFUSE JUVENILE SYSTEMIC SCLEROSIS PATIENTS SHOW DISTINCT ORGAN INVOLVEMENT, ANTIBODY PATTERN AND HAVE SIGNIFICANTLY MORE SEVERE DISEASE IN THE LARGEST JSSC COHORT OF THE WORLD. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT

17. POS0140 PATIENT AND PHYSICIAN REPORTED OUTCOMES OF JUVENILE SYSTEMIC SCLEROSIS PATIENTS SIGNIFICANTLY IMPROVE OVER 24 MONTHS OBSERVATION PERIOD IN THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT

18. POS0141 APPLICATION OF CRISS SCORE, REVISED CRISS SCORE AND RCID SCORE IN PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS

19. POS1570 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN FAMILIAL MEDITERRANEAN FEVER (FMF) – 36-MONTH DATA FROM THE RELIANCE REGISTRY

20. POS1558 LONG-TERM SAFETY OF CANAKINUMAB IN AUTOINFLAMMATORY PERIODIC FEVER SYNDROMES – 48-MONTH DATA FROM THE RELIANCE REGISTRY

21. OP0252 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) – 4-YEARS DATA FROM THE RELIANCE REGISTRY

22. Application of CRISS score, revised CRISS score and RCID score in patients with Juvenile systemic sclerosis

23. Entwicklung und psychometrische Validierung eines Selbsterhebungs-Instrumentes zur übergreifenden Erfassung von Kompetenzen, ungedeckten Bedarfen und der Zufriedenheit im Transitionsprozess

24. Versorgungssituation junger Rheumatiker mit chronischen Arthritiden - eine bevölkerungsbezogene Umfrage

25. 24-Monats-Daten zu Wirksamkeit und Sicherheit von Tocilizumab im Vergleich zu TNF Inhibitoren bei polyartikulärer juveniler idiopathischer Arthritis

26. Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 24 months observation period in the juvenile systemic scleroderma inception cohort

27. Elternberichtete-Outcomes und Therapiezufriedenheit im ersten Behandlungsjahr bei JIA, SLE und JDM - Interimsergebnisse aus ProKind-Rheuma

28. Langzeitwirksamkeit von Canakinumab bei autoinflammatorischen periodischen Syndromen - Interimsanalyse des RELIANCE-Registers

29. Führt die Langzeitbehandlung mit Canakinumab bei autoinflammatorischen periodischen Fiebersyndromen vermehrt zu Infektionen? 48-Monats-Daten des RELIANCE-Registers

30. Diffuse juvenile systemic sclerosis patients show distinct organ involvement, antibody pattern and have significantly more severe disease in the largest jSSc cohort of the world. Results from the juvenile scleroderma inception cohort

31. Is decreased body mass index-2 z score or less correlating with an organ involvement pattern? Results from the juvenile scleroderma inception cohort

32. Auswirkungen der Coronavirus-Pandemie auf Patienten mit autoinflammatorischen periodischen Syndromen unter Canakinumab-Behandlung - Interimsergebnisse aus dem RELIANCE-Register

33. Prävalenz und Korrelate von Angst- und Depressionssymptomen bei Jugendlichen und jungen Erwachsenen mit juveniler idiopathischer Arthritis (JIA): Ergebnisse aus COACH

38. Diffuse juvenile systemic sclerosis patients show distinct organ involvement and have more severe disease in the largest jSSc cohort of the world. Results from the the juvenile scleroderma inception cohort

39. Depressive und ängstliche Symptome bei Patienten mit juveniler idiopathischer Arthritis (JIA) - Daten aus der Inzeptionskohorte neu diagnostizierter Kinder und Jugendlicher mit JIA (ICON)

40. Juvenile systemic sclerosis treatment practices in an international cohort and comparison to recent SHARE consensus guidelines

41. Behandlung und Outcomes neu diagnostizierter Patient:innen mit polyartikulärer juveniler idiopathischer Arthritis (pJIA) - erste Ergebnisse aus ProKind-Rheuma

42. Wirksamkeit und Sicherheit von IL-6-Inhibition (Tocilizumab) im Vergleich zu TNF-Inhibition bei polyartikulärer juveniler idiopathischer Arthritis: Ergebnisse aus dem BIKER-Register

43. Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 12 months observation period in the juvenile systemic scleroderma inception cohort

44. Clinical characteristics of juvenile onset systemic sclerosis patients from the juvenile scleroderma inception cohort compared to adult age juvenile-onset patients from EUSTAR. Are these differences suggesting risk for mortality?

46. Verlauf der Uveitis bei Kindern mit juveniler idiopathischer Arthritis: Daten aus der Inzeptionskohorte ICON-JIA

47. Impfsicherheit unter Canakinumab bei Patienten mit autoinflammatorischen periodischen Syndromen - Interimsanalyse des RELIANCE-Registers

48. Gesundheitsbezogene Transitionskompetenz bei Jugendlichen und jungen Erwachsenen mit juveniler idiopathischer Arthritis (JIA)

49. Langzeitsicherheit und Wirksamkeit von Canakinumab bei Cryopyrin-assoziierten periodischen Syndromen (CAPS) - 36-Monats-Daten aus dem RELIANCE-Register

50. Langzeitwirksamkeit und Sicherheit von Canakinumab bei Patienten mit familiärem Mittelmeerfieber (FMF) - Zwischenanalyse des RELIANCE-Registers

Catalog

Books, media, physical & digital resources